Microbiological Quality of Blister Pack Tablets in Community Pharmacies in Jordan
Purpose: To investigate the microbiological quality of blister-packed tablets manufactured and marketed in Jordan in order to assess Good Manufacturing Practice by pharmaceutical industries in the country.
Methods: A total of 66 items of 22 registered blister-packed tablet brands were purchased from community pharmacies in Amman. All the items were investigated for total bacterial count and the presence of specified microorganisms using compendial procedures.
Results: Out of 66 items purchased, forty eight (72.7 %) products were free from microbial contamination, while 11 (16.7 %) harbored bacteria in counts < 102 cfu/g. The remaining 7 (10.6 %) items contained counts between 102 and < 103 cfu/g. The most commonly encountered contaminant was Bacillus species but specified objectionable bacteria such as Escherichia coli and Staphylococcus aereus were not detected. Aspergillus and Penicillium species were isolated in low numbers from few products. Six of the products with the highest stratified bacterial count were manufactured by one company and were also found to be contaminated with Aeromonas species.
Conclusion: This study demonstrates that blister-packed tablets produced by Jordanian pharmaceutical companies are within acceptable microbiological quality but the detection of microbial load in some brands close to the maximum allowable limit suggests the need for better adherence to GMP in the country.
Keywords: Blister pack, Community pharmacy, Good Manufacturing Practice, Microbial contamination,Quality control, Tablets
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.